MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the Company’s Tri-Staple™ technology platform has achieved more than $1 Billion in product sales since launching in mid-2010. Covidien’s Tri-Staple technology platform for endoscopic surgical stapling is the first-of-its-kind technology that enables surgeons to use staplers in a broader range of tissue thicknesses than ever before. Surgeons have rapidly adopted and use Tri-Staple technology reloads across surgical specialties including bariatric, thoracic, colorectal, general, hepatobiliary and gynecological surgery. Endo GIA™ Reloads with Tri-Staple technology are sold in more than 45 countries.
